Results 101 to 110 of about 30,437 (208)

Evaluation of the Safety, Efficacy and Pharmacokinetics of BGM0504 in Chinese Adults With Type 2 Diabetes: A Multicentre, Randomised, Controlled and Double‐Blind Phase II Trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7073-7082, August 2026.
ABSTRACT Aim This study aimed to evaluate its safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy in Chinese adults with T2DM and to preliminarily compare its efficacy and safety with semaglutide through multiple subcutaneous injections. Materials and Methods In this multicentre, randomised, placebo‐controlled and semaglutide‐positive‐
Ping Jin, Linong Ji, Yangqing Huang, Haifeng Ding, Daosheng Xie, Xiaohui Jiang, Xuemei Yuan, Zhao Cao, Haibin Zhang, Jiandong Yuan   +9 more
wiley   +1 more source

Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE‐JP Trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6595-6606, August 2026.
ABSTRACT Aims There is an unmet need for effective pharmacotherapy for obesity disease management in Japan. Survodutide is a novel glucagon receptor/glucagon‐like peptide‐1 receptor (GLP‐1R) dual agonist with the potential to induce greater weight reductions than GLP‐1R mono‐agonists. We report the design and baseline participant characteristics of the
Koutaro Yokote, Toshimasa Yamauchi, Yasushi Fukushima, Yoji Takatsuka, Marie Kato, Shijia Yan, Takayoshi Inoue, Luiza Borowska, Martina Brueckmann, Wataru Ogawa, on behalf of the SYNCHRONIZE‐JP Trial Investigators   +10 more
wiley   +1 more source

Semaglutide Injection in Indian Patients With Type 2 Diabetes Mellitus: A Randomised, Phase III, Active‐Controlled Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7094-7103, August 2026.
ABSTRACT Aim To evaluate the efficacy, safety and immunogenicity of semaglutide injection (synthetic) (Test group) compared with the Reference semaglutide injection [Ozempic, (Reference group)] in Indian patients with Type 2 diabetes mellitus (T2DM).
Unnikrishnan Ambika Gopalakrishnan, Ameya Sudhakar Joshi, Richa Giri, Shalin Jagdeep Shah, Jitendra Shukla, Sanjiv Maheshwari, Rekha M. Chowdaiah, Manish Kumar Singh, Aditya Srirang Bari, Niranjan Pandurang Pathak, Akash Nitinbhai Shah, Shweta Bhandari, Ambanna Gowda, Ambrish Chandrappa, Pravin Dinkar Supe, Bharat Das, Prabhat Kumar Sharma, Mehul Kalubhai Virani, Prakash Harishchandra Kurmi, Gayatri Amit Ghanekar, Mani Deepathi Dasari, Banshidhar Sahoo, Sanjay Kumar Jangid, Prakash Sadashiv Shende, Sandesh Sahebarao Patil, Avinash Narayan Kumbhar, Shrikant Vishnu Deshpande, Madhusudhan Chennappa, Nitesh Chandubhai Patel, Dipesh Sonawane, Dipak Patil, Sucheta Pandit, Pravin Ghadge, Suyog Mehta   +33 more
wiley   +1 more source

Real‐World Effectiveness and 12‐Month Persistence of a Semaglutide‐Supported Digital Weight‐Loss Service: A Retrospective Cohort Study in Germany

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6985-6996, August 2026.
ABSTRACT Aim To evaluate the 12‐month effectiveness and patient persistence of a semaglutide‐supported digital weight‐loss service (DWLS) in a real‐world German cohort. Methods This retrospective study analysed 4535 patients who initiated the Juniper Germany DWLS. Primary endpoints included 12‐month medication and data submission adherence (receiving ≥ 
Louis Talay, Jason Hom, Marilyn Tan, Neera Ahuja   +3 more
wiley   +1 more source

FNAC diagnosis of medullary carcinoma thyroid: A report of three cases with review of literature

Journal of Cytology, 2010
Medullary carcinoma of the thyroid is an unusual neoplasm, which is associated with specific supportive diagnostic markers. Despite this, its cytological diagnosis is often difficult. We report herewith three cases of medullary thyroid carcinoma.
Mehdi Ghazala, Maheshwari Veena, Ansari Hena, Sadaf Lubna, Khan Mohammad   +4 more
doaj  

FOXA1 is a highly sensitive diagnostic marker for prostate cancer including small cell carcinoma of the prostate

Histopathology, Volume 89, Issue 2, Page 240-250, August 2026.
FOXA1 is a highly sensitive diagnostic marker for prostate cancer. Besides prostatic adenocarcinoma, it is also expressed in 57%–80% of metastatic or primary prostatic small cell carcinomas, which lose traditional prostatic markers including NKX3.1. Although it is less specific than NKX3.1, it can serve as a valuable adjunct for confirming prostatic ...
Jianping Zhao, Jun Yao, Hossein Hosseini, Ezra Baraban, Ruihe Lin, Charles C. Guo, Lei Huo, Wei Lu, Khaja Khan, Shufang Wang, Luisa Maren Solis Soto, Qingqing Ding   +11 more
wiley   +1 more source

Medullary Thyroid Carcinoma in a Horse [PDF]

Veterinary Pathology, 1986
M A, van der Velden, H, Meulenaar
openaire   +2 more sources

Five Advances in the Last 50 Years That Have Impacted Endocrine Surgery

World Journal of Surgery, Volume 50, Issue 8, Page 2071-2076, August 2026.
Matilda Anneback, Priya H. Dedhia, Aimee Di Marco, Els Nieveen van Dijkum, Julie A. Miller, Janice L. Pasieka   +5 more
wiley   +1 more source

Metastatic medullary thyroid carcinoma: A case report

Journal of Research in Medical Sciences, 2011
Medullary thyroid carcinoma accounts for 4% of thyroid carcinoma and originates from parafollicular cells, secreting calcitonin and carcinoembryonic antigen (CEA).
Mitra Niafar, Shahram Dabiri, Farshid Bozorgi, Farid Niafar, Nasrin Gholami   +4 more
doaj  

Clinical pathological characteristics and prognostic analysis of 140 cases of medullary thyroid carcinoma: validation of the international medullary thyroid carcinoma grading system in a chinese cohort. [PDF]

Diagn Pathol
Zhang Z, Yang Y, Dou Y, Liu W, Dong L, Zhu Y, Lu H.   +6 more
europepmc   +1 more source